pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2011-0-3-113-117pulmo-340Research ArticleОБЗОРЫREVIEWФенотипы больных хронической обструктивной болезнью легких и исследование ECLIPSE: первые результатыPhenotypes of chronic obstructive pulmonary disease and the ECLIPSE study: preliminary resultsОвчаренкоС. И.OvcharenkoS. I.

д. м. н., проф. кафедры факультетской терапии № 1 лечебного факультета

119991, Москва, ул. Б. Пироговская, 6. Тел.: (499) 248-56-67.

svetftk@mail.ruГОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова"Russian Federation20112806201103113117Copyright © Овчаренко С.И., 20112011Овчаренко С.И.Ovcharenko S.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/340

Фенотипы больных хронической обструктивной болезнью легких и исследование ECLIPSE: первые результаты.

Phenotypes of chronic obstructive pulmonary disease and the ECLIPSE study: preliminary results.

ХОБЛфенотипычастые обостренияобъем форсированного выдоха за 1-ю секундутяжестьchronic obstructive pulmonary diseasephenotypesfrequent exacerbations. forced expiratory volume for 1 sseverityReferencesЧучалин А.Г. (ред.). Хроническая обструктивная болезнь легких. (Федеральная программа): Практическое руководство для врачей. 2-е изд. М.; 2004.Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких. (Федеральная программа): Практическое руководство для врачей. 2-е изд. М.; 2004.Buist S., McBurnie, Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.Buist S., McBurnie, Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–750.Celli B.R., MacNee W., Agusti A.G. et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.Celli B.R., MacNee W., Agusti A.G. et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176 (6): 532–555.Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176 (6): 532–555.Committee for proprietary medicinal products points to consider on clinical investigation of medicine products in the chronic treatment of patients with COPD. London; 1999. 562–598.Committee for proprietary medicinal products points to consider on clinical investigation of medicine products in the chronic treatment of patients with COPD. London; 1999. 562–598.Jones P.W., Agusti A. Outcomes and markers of chronic obstructive pulmonary disease. Eur. Resp. J. 2006; 27: 822–832.Jones P.W., Agusti A. Outcomes and markers of chronic obstructive pulmonary disease. Eur. Resp. J. 2006; 27: 822–832.Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416–469.Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416–469.Han MeiLan K., Agusti A., Calverely P. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 598–604.Han MeiLan K., Agusti A., Calverely P. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 598–604.Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких. M.: Атмосфера; 2008.Чучалин А.Г. (ред.). Хроническая обструктивная болезнь легких. M.: Атмосфера; 2008.Овчаренко С.И., Капустина В.А. Хроническая обструктивная болезнь легких: особенности у женщин. Пульмонология 2009; 2: 102–112.Овчаренко С.И., Капустина В.А. Хроническая обструктивная болезнь легких: особенности у женщин. Пульмонология 2009; 2: 102–112.Vestbo J., Anderson W., Coxson H.O. et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoint (ECLIPSE). Eur. Respir. J. 2008; 31: 869–873.Vestbo J., Anderson W., Coxson H.O. et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoint (ECLIPSE). Eur. Respir. J. 2008; 31: 869–873.Agusti A., Calverely P., Celli B. et al. Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.Agusti A., Calverely P., Celli B. et al. Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.Kanner R.E., Anthonisen N.R., Connett J.E. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 358–364.Kanner R.E., Anthonisen N.R., Connett J.E. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 358–364.Donaldson G.C., Seemungal T.A., Bhowmik A. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.Donaldson G.C., Seemungal T.A., Bhowmik A. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.Donaldson G.C., Wilkinson T.M.A., Hurst J.R. et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 446–452.Donaldson G.C., Wilkinson T.M.A., Hurst J.R. et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 446–452.Seemungal T.A., Donaldson G.C, Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157 (5, Pt 1): 1418–1422.Seemungal T.A., Donaldson G.C, Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157 (5, Pt 1): 1418–1422.Soler5Cataluna J.J., Martinez5Garcia M.A., Roman Sanchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–931.Soler5Cataluna J.J., Martinez5Garcia M.A., Roman Sanchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–931.Sullivan S.D., Ramsey S.D., Lee T.A. The economic burden of COPD*. Chest 2000; 117 (2, Suppl.): 5S–9S.Sullivan S.D., Ramsey S.D., Lee T.A. The economic burden of COPD*. Chest 2000; 117 (2, Suppl.): 5S–9S.Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.

The authors declare that there are no conflicts of interest present.